Does Metformin have a role in Preventing Long COVID?

A new study has pointed to the potential effect of metformin on Long COVID Patients and preventing the development of chronic symptoms.

Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2023-04-13 04:00 GMT   |   Update On 2023-04-13 08:59 GMT
Advertisement

Metformin, a drug commonly used to treat diabetes may have a promising role in preventing the chronic consequences of COVID-19 also known as Long COVID, a new preprint study published by The Lancet has pointed out. The preprint hasn’t been peer-reviewed or published in a journal.

The post-acute consequences of COVID-19 known as Long COVID is an emerging chronic illness possibly affecting around 10% of those previously infected by the virus. The symptoms associated with Long COVID or Post Acute Sequelae of COVID (PASC) are multivarious and differ from patient to patient, they may range from a single symptom to a serious multi-organ failure. The symptoms can be mild and merciful or chronically life-threatening. The most common symptoms of Long COVID include- fatigue, breathlessness on exertion, persistent cough, muscular and joint pain, deficiencies in hearing and sight, and persistent loss of smell and taste. The study conducted by Bramante et al aimed to assess the outpatient treatment with metformin, ivermectin, or fluvoxamine on Long COVID symptoms.

Advertisement

Bramante and colleagues conducted a multi-site, Phase 3 randomized, quadruple-blinded placebo-controlled trial as outpatient treatment of SARS-CoV-2 that used a 2 x 3 factorial design of parallel treatments. Metformin (used typically in Type 2 Diabetes regimen), Ivermectin (an antiparasitic drug), and Fluvoxamine (an antidepressant drug) were used in this trial called COVID OUT. Participants, care providers, investigators, and outcome assessors were blinded.

The patients selected were aged 30 to 85 years with overweight or obesity by self-reported body mass index (BMI); documentation of confirmed SARS-CoV-2 infection, and vaccination against SARS-CoV-2 was not an exclusion criterion. The trial was 1:1 randomization to Metformin vs. placebo.

Pregnant and lactating women were not excluded. Pregnant and lactating women were randomized 1:1 to metformin or placebo, not fluvoxamine or ivermectin due to less established literature for safety during pregnancy and lactation for those medications.

The study revealed the following finding:

  • Of the 1323 randomized trial participants, 8.4% reported a medical provider diagnosed them with Long COVID; cumulative incidence: 6.3% with metformin and 10.6% with matched placebo.
  • The metformin effect was consistent across subgroups, including viral variants.
  • No statistical difference in Long COVID occurred in those randomized to either ivermectin or fluvoxamine.
  • A 42% relative decrease and 4.3% absolute decrease in the Long COVID incidence occurred in participants who received early outpatient COVID-19 treatment with metformin compared to an exact-matching placebo.
The results published by Bramante et al, are currently in the pre-print stage and under journal review. The COVID OUT Trial does not indicate the long-term efficiency of averting Long COVID symptoms if started at the time of emergency or hospitalization. The trial also did not explain the drug’s mechanism of action against Long COVID sequelae, only being a first step in exploring the role of Metformin in Long COVID. Further large-scale studies need to be conducted to test the effectiveness of the treatment in the long run.

References:

Bramante, Carolyn and Buse, John B. and Liebovitz, David and Nicklas, Jacinda and Puskarich, Michael and Cohen, Kenneth R. and Belani, Hrishikesh and Anderson, Blake and Huling, Jared D. and Tignanelli, Christopher and Thompson, Jennifer and Pullen, Matthew and Wirtz, Esteban Lemus and Siegel, Lianne and Proper, Jennifer and Odde, David J. and Klatt, Nichole and Sherwood, Nancy E. and Lindberg, Sarah and Karger, Amy B. and Beckman, Kenneth B. and Erickson, Spencer and Fenno, Sarah and Hartman, Katrina and Rose, Michael and Mehta, Tanvi and Patel, Barkha and Griffiths, Gwendolyn and Bhat, Neeta and Murray, Thomas A. and Boulware, David R., Outpatient Treatment of COVID-19 and the Development of Long COVID Over 10 Months: A Multi-Center, Quadruple-Blind, Parallel Group Randomized Phase 3 Trial. Available at SSRN: https://ssrn.com/abstract=4375620 or http://dx.doi.org/10.2139/ssrn.4375620

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News